IMDX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IMDX vs LLY: Head-to-Head Comparison
This page compares Insight Molecular Diagnostics Inc. (IMDX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.